IR Materials — ST PHARM

Science & Technology
- Business Overview
- CDMO
- CRO
  - AnaPath Research & Service
- R&D
  - Virtual R&D
  - Global R&D
About
Public
- PR (Public Relations)
  - News room
- IR (Investor Relations)
  - Stock Information
  - IR Library
Careers
ESG

Linkedin

Public

IR Materials

PR (Public Relations)
- News room
IR (Investor Relations)
- Stock Information
- IR Library

IR Library

[Update] IR Material based on 3Q Quarterly Report Nov 19, 2024

[IR Material] Macquarie Securities Korea NDR (Hong Kong / Singapore) Nov 1, 2024

[Earning Call] 2024 3rd Quarter Earning Call Presentation Material Nov 1, 2024

[IR Material] Korea Investment Week 2024 Sep 6, 2024

[IR Materials] mRNA Platform Technology Mar 14, 2023

[Analyst Report] 4Q review: Oligo-driven strength Feb 17, 2023

[Earnings Summary] ST PHARM 4Q. 2022 Earnings Summary Feb 17, 2023

[Presentation] ST PHARM IR Preentation (Feb. 2023) Feb 6, 2023

[Analyst Report] Fundamentals intact despite noise Jan 16, 2023

[Analyst Report] Value of mRNA platform growing Dec 16, 2022

[Analyst Report] 3Q disappoints as clients adjust production volume Nov 1, 2022

[Analyst Report] Forward path clear Oct 20, 2022

[Analyst Report] OP in line on growing oligonucleotide sales Aug 11, 2022

[Presentation] ST PHARM IR Presentation (August 2022) Aug 5, 2022

1of2